Cargando…

Patterns of patients with polypharmacy in adult population from Korea

Polypharmacy and its rising global prevalence is a growing public health burden. Using a large representative nationwide Korean cohort (N = 761,145), we conducted a retrospective cross-sectional study aiming to identify subpopulations of patients with polypharmacy and characterize their unique patte...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Woo-young, Go, Tae-Hwa, Kang, Dae Ryong, Lee, Sei Young, Lee, Won, Kim, Seonah, Lee, Jiewon, Kim, Jung-ha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613698/
https://www.ncbi.nlm.nih.gov/pubmed/36302935
http://dx.doi.org/10.1038/s41598-022-23032-z
_version_ 1784820032544440320
author Shin, Woo-young
Go, Tae-Hwa
Kang, Dae Ryong
Lee, Sei Young
Lee, Won
Kim, Seonah
Lee, Jiewon
Kim, Jung-ha
author_facet Shin, Woo-young
Go, Tae-Hwa
Kang, Dae Ryong
Lee, Sei Young
Lee, Won
Kim, Seonah
Lee, Jiewon
Kim, Jung-ha
author_sort Shin, Woo-young
collection PubMed
description Polypharmacy and its rising global prevalence is a growing public health burden. Using a large representative nationwide Korean cohort (N = 761,145), we conducted a retrospective cross-sectional study aiming to identify subpopulations of patients with polypharmacy and characterize their unique patterns through cluster analysis. Patients aged ≥ 30 years who were prescribed at least one medication between 2014 and 2018 were included in our study. Six clusters were identified: cluster 1 mostly included patients who were hospitalized for a long time (4.3 ± 5.3 days); cluster 2 consisted of patients with disabilities (100.0%) and had the highest mean number of prescription drugs (7.7 ± 2.8 medications); cluster 3 was a group of low-income patients (99.9%); cluster 4 was a group of high-income patients (80.2%) who frequently (46.4 ± 25.9 days) visited hospitals/clinics (7.3 ± 2.7 places); cluster 5 was mostly elderly (74.9 ± 9.8 years) females (80.3%); and cluster 6 comprised mostly middle-aged (56.4 ± 1.5 years) males (88.6%) (all P < 0.001). Patients in clusters 1–5 had more prescribed medications and outpatient visit days than those in cluster 6 (all P < 0.001). Given limited health care resources, individuals with any of the identified phenotypes may be preferential candidates for participation in intervention programs for optimal medication use.
format Online
Article
Text
id pubmed-9613698
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96136982022-10-29 Patterns of patients with polypharmacy in adult population from Korea Shin, Woo-young Go, Tae-Hwa Kang, Dae Ryong Lee, Sei Young Lee, Won Kim, Seonah Lee, Jiewon Kim, Jung-ha Sci Rep Article Polypharmacy and its rising global prevalence is a growing public health burden. Using a large representative nationwide Korean cohort (N = 761,145), we conducted a retrospective cross-sectional study aiming to identify subpopulations of patients with polypharmacy and characterize their unique patterns through cluster analysis. Patients aged ≥ 30 years who were prescribed at least one medication between 2014 and 2018 were included in our study. Six clusters were identified: cluster 1 mostly included patients who were hospitalized for a long time (4.3 ± 5.3 days); cluster 2 consisted of patients with disabilities (100.0%) and had the highest mean number of prescription drugs (7.7 ± 2.8 medications); cluster 3 was a group of low-income patients (99.9%); cluster 4 was a group of high-income patients (80.2%) who frequently (46.4 ± 25.9 days) visited hospitals/clinics (7.3 ± 2.7 places); cluster 5 was mostly elderly (74.9 ± 9.8 years) females (80.3%); and cluster 6 comprised mostly middle-aged (56.4 ± 1.5 years) males (88.6%) (all P < 0.001). Patients in clusters 1–5 had more prescribed medications and outpatient visit days than those in cluster 6 (all P < 0.001). Given limited health care resources, individuals with any of the identified phenotypes may be preferential candidates for participation in intervention programs for optimal medication use. Nature Publishing Group UK 2022-10-27 /pmc/articles/PMC9613698/ /pubmed/36302935 http://dx.doi.org/10.1038/s41598-022-23032-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Shin, Woo-young
Go, Tae-Hwa
Kang, Dae Ryong
Lee, Sei Young
Lee, Won
Kim, Seonah
Lee, Jiewon
Kim, Jung-ha
Patterns of patients with polypharmacy in adult population from Korea
title Patterns of patients with polypharmacy in adult population from Korea
title_full Patterns of patients with polypharmacy in adult population from Korea
title_fullStr Patterns of patients with polypharmacy in adult population from Korea
title_full_unstemmed Patterns of patients with polypharmacy in adult population from Korea
title_short Patterns of patients with polypharmacy in adult population from Korea
title_sort patterns of patients with polypharmacy in adult population from korea
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613698/
https://www.ncbi.nlm.nih.gov/pubmed/36302935
http://dx.doi.org/10.1038/s41598-022-23032-z
work_keys_str_mv AT shinwooyoung patternsofpatientswithpolypharmacyinadultpopulationfromkorea
AT gotaehwa patternsofpatientswithpolypharmacyinadultpopulationfromkorea
AT kangdaeryong patternsofpatientswithpolypharmacyinadultpopulationfromkorea
AT leeseiyoung patternsofpatientswithpolypharmacyinadultpopulationfromkorea
AT leewon patternsofpatientswithpolypharmacyinadultpopulationfromkorea
AT kimseonah patternsofpatientswithpolypharmacyinadultpopulationfromkorea
AT leejiewon patternsofpatientswithpolypharmacyinadultpopulationfromkorea
AT kimjungha patternsofpatientswithpolypharmacyinadultpopulationfromkorea